The Impact of Type 2 Diabetes in Parkinson's DiseaseDilan Athauda, Sonia Gandhi, Yoav Ben‐Shlomo et al.|Movement Disorders|2022Cited by 131
GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppressionDilan Athauda, Sonia Gandhi, James R. Evans et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 7
The impact of Type 2 diabetes in Parkinson’s diseaseDilan Athauda, Sonia Gandhi, James R. Evans et al.|medRxiv|2021Cited by 3
The Impact of Type 2 Diabetes in Parkinson's DiseaseDilan Athauda, Sonia Gandhi, James R. Evans et al.|SSRN Electronic Journal|2021Cited by 0